Literature DB >> 3048759

Effectiveness of amodiaquine, sulfadoxine-pyrimethamine, and combinations of these drugs for treating chloroquine-resistant falciparum malaria in Hainan Island, China.

O L Huang, W C Ouyang, J X Zhou, Z Wu, K Y Zhang, J K Huang, X Z Cai, X J Pang, S G Fu, X F Wang.   

Abstract

The study was carried out in 1985-86 in Hainan Island where Plasmodium falciparum is resistant to chloroquine. Fifty cases of falciparum malaria were treated with 1800 mg amodiaquine for 3 days: the cure rate was 65.3%, and the mean time to clear fever and asexual parasitaemia was 30.7 and 60.3 hours, respectively; 34.7% of cases showed RI or RII recrudescence, and one patient's temperature did not come down to normal within 7 days.Twenty-one cases were treated with sulfadoxine-pyrimethamine (1500 mg and 75 mg, respectively): 19 were cured, I showed RI and another had an S or RI response; the mean time for fever control was 56.1 hours.Fifty cases were treated with amodiaquine plus sulfadoxine and 49 received amodiaquine plus sulfadoxine-pyrimethamine: the cure rate was 97.9% and 100%, respectively; the mean time for fever clearance was 25.0 and 25.7 hours and for parasite clearance 57.1 and 52.8 hours, respectively. These drug combinations gave much better results for cure and for symptom control than amodiaquine or sulfadoxine-pyrimethamine alone, and may be considered for treatment of chloroquine-resistant falciparum malaria.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3048759      PMCID: PMC2491139     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  5 in total

1.  Plasmodium falciparum malaria in Panama resistant to 4-aminoquinoline drugs.

Authors:  M D Young; C M Johnson
Journal:  Am J Trop Med Hyg       Date:  1972-01       Impact factor: 2.345

2.  [A successive survey on the sensitivity of P. falciparum patients to chloroquine by in vitro microtechnic and in vivo test on Hainan Island].

Authors:  Q L Huang
Journal:  Zhonghua Yu Fang Yi Xue Za Zhi       Date:  1985-07

Review 3.  Advances in chemotherapy.

Authors:  R E Howells
Journal:  Br Med Bull       Date:  1982-05       Impact factor: 4.291

4.  Treatment of Plasmodium falciparum malaria with a combination of amodiaquine and tetracycline in Central Thailand.

Authors:  S Noeypatimanond; S Malikul; W Benjapong; D Duriyananda; M Ungkasrithongkul
Journal:  Trans R Soc Trop Med Hyg       Date:  1983       Impact factor: 2.184

5.  Evaluation of amodiaquine treatment of chloroquine-resistant Plasmodium falciparum malaria on Zanzibar, 1982.

Authors:  C C Campbell; D Payne; I K Schwartz; O J Khatib
Journal:  Am J Trop Med Hyg       Date:  1983-11       Impact factor: 2.345

  5 in total
  5 in total

1.  Malaria in selected non-Amazonian countries of Latin America.

Authors:  Myriam Arevalo-Herrera; Martha Lucia Quiñones; Carlos Guerra; Nora Céspedes; Sandra Giron; Martha Ahumada; Juan Gabriel Piñeros; Norma Padilla; Zilka Terrientes; Angel Rosas; Julio Cesar Padilla; Ananias A Escalante; John C Beier; Socrates Herrera
Journal:  Acta Trop       Date:  2011-07-01       Impact factor: 3.112

Review 2.  Treatment of malaria--1990.

Authors:  D M Panisko; J S Keystone
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

Review 3.  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.

Authors:  H M McIntosh; K L Jones
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

4.  Surveillance of antimalarial drug resistance in China in the 1980s-1990s.

Authors:  De-Quan Liu
Journal:  Infect Dis Poverty       Date:  2014-02-24       Impact factor: 4.520

5.  Genomic Epidemiology of Antimalarial Drug Resistance in Plasmodium falciparum in Southern China.

Authors:  Fang Huang; Christopher G Jacob; Shannon Takala-Harrison; Matthew Adams; Heng-Lin Yang; Hui Liu; Zhi-Gui Xia; Shui-Sen Zhou; Lin-Hua Tang; Christopher V Plowe
Journal:  Front Cell Infect Microbiol       Date:  2021-01-08       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.